Search Result

Results for "

Aminooxy-PEG3-bromide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endothelin Receptor (1) GCGR (3) GLP Receptor (2) PKA (1) PROTAC Linkers (4) Somatostatin Receptor (3)
By Research Areas:	Cancer (8) Cardiovascular Disease (2) Metabolic Disease (4) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-140396C

Aminooxy-PEG3-bromide hydrobromide

PROTAC Linkers Cancer

Aminooxy-PEG3-bromide hydrobromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
HY-140396

Aminooxy-PEG3-bromide

PROTAC Linkers Cancer

Aminooxy-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
HY-140396A

Aminooxy-PEG3-bromide hydrochloride

PROTAC Linkers Cancer

Aminooxy-PEG3-bromide hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
HY-140435

Boc-Aminooxy-PEG3-bromide

PROTAC Linkers Cancer

Boc-Aminooxy-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

Aminooxy-PEG3-bromide hydrobromide	PROTAC Linkers	Cancer
Aminooxy-PEG3-bromide hydrobromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

**Aminooxy-PEG3-bromide**	PROTAC Linkers	Cancer
Aminooxy-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

Aminooxy-PEG3-bromide hydrochloride	PROTAC Linkers	Cancer
Aminooxy-PEG3-bromide hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

Boc-Aminooxy-PEG3-bromide	PROTAC Linkers	Cancer
Boc-Aminooxy-PEG3-bromide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-P5362

NODAGA-LM3	Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas .

HY-P5362A

NODAGA-LM3 TFA	Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas .

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

Cat. No.	Product Name	Target	Research Area

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P5112

Azido-PEG3-DYKDDDDK

Peptides Others

Azido-PEG3-DYKDDDDK is a peptide.
HY-P4757

N1-Glutathionyl-spermidine disulfide

Peptides Others

N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

Azido-PEG3-DYKDDDDK	Peptides	Others
Azido-PEG3-DYKDDDDK is a peptide.

N1-Glutathionyl-spermidine disulfide	Peptides	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-P5362

NODAGA-LM3	Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas .

HY-P5362A

NODAGA-LM3 TFA	Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas .

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.